192 related articles for article (PubMed ID: 38403632)
21. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
[TBL] [Abstract][Full Text] [Related]
22. Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy.
Kawasaki T; Miwa K; Shinoda J; Asano Y; Takei H; Ikegame Y; Yokoyama K; Yano H; Iwama T
World Neurosurg; 2019 May; 125():93-100. PubMed ID: 30716494
[TBL] [Abstract][Full Text] [Related]
23. Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From
Qian J; Herman MG; Brinkmann DH; Laack NN; Kemp BJ; Hunt CH; Lowe V; Pafundi DH
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1339-1346. PubMed ID: 32634544
[TBL] [Abstract][Full Text] [Related]
24. l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy.
Mahasittiwat P; Mizoe JE; Hasegawa A; Ishikawa H; Yoshikawa K; Mizuno H; Yanagi T; Takagi R; Pattaranutaporn P; Tsujii H
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):515-22. PubMed ID: 17900820
[TBL] [Abstract][Full Text] [Related]
25. A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.
Su X; Sun H; Chen N; Roberts N; Yang X; Wang W; Li J; Huang X; Gong Q; Yue Q
Clin Radiol; 2020 Dec; 75(12):963.e7-963.e15. PubMed ID: 32921406
[TBL] [Abstract][Full Text] [Related]
26. Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models.
Choi Y; Nam Y; Jang J; Shin NY; Lee YS; Ahn KJ; Kim BS; Park JS; Jeon SS; Hong YG
Eur Radiol; 2021 Apr; 31(4):2084-2093. PubMed ID: 33006658
[TBL] [Abstract][Full Text] [Related]
27.
Kong Z; Jiang C; Zhu R; Feng S; Wang Y; Li J; Chen W; Liu P; Zhao D; Ma W; Wang Y; Cheng X
Neuroimage Clin; 2019; 23():101912. PubMed ID: 31491820
[TBL] [Abstract][Full Text] [Related]
28. Differentiating solitary brain metastases from glioblastoma by radiomics features derived from MRI and 18F-FDG-PET and the combined application of multiple models.
Cao X; Tan D; Liu Z; Liao M; Kan Y; Yao R; Zhang L; Nie L; Liao R; Chen S; Xie M
Sci Rep; 2022 Apr; 12(1):5722. PubMed ID: 35388124
[TBL] [Abstract][Full Text] [Related]
29. Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study.
Harat M; Małkowski B; Makarewicz R
Radiother Oncol; 2016 Aug; 120(2):241-7. PubMed ID: 27378734
[TBL] [Abstract][Full Text] [Related]
30. Radiomics Multifactorial in Silico Model for Spatial Prediction of Glioblastoma Progression and Recurrence: A Proof-of-Concept.
Luzzi S; Agosti A
World Neurosurg; 2024 Mar; 183():e677-e686. PubMed ID: 38184226
[TBL] [Abstract][Full Text] [Related]
31. Feasibility on the Use of Radiomics Features of 11[C]-MET PET/CT in Central Nervous System Tumours: Preliminary Results on Potential Grading Discrimination Using a Machine Learning Model.
Russo G; Stefano A; Alongi P; Comelli A; Catalfamo B; Mantarro C; Longo C; Altieri R; Certo F; Cosentino S; Sabini MG; Richiusa S; Barbagallo GMV; Ippolito M
Curr Oncol; 2021 Dec; 28(6):5318-5331. PubMed ID: 34940083
[TBL] [Abstract][Full Text] [Related]
32. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
[TBL] [Abstract][Full Text] [Related]
33. [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.
Pötzi C; Becherer A; Marosi C; Karanikas G; Szabo M; Dudczak R; Kletter K; Asenbaum S
J Neurooncol; 2007 Sep; 84(3):305-14. PubMed ID: 17492401
[TBL] [Abstract][Full Text] [Related]
34. Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.
Hirono S; Hasegawa Y; Sakaida T; Uchino Y; Hatano K; Iuchi T
Sci Rep; 2019 Nov; 9(1):17794. PubMed ID: 31780768
[TBL] [Abstract][Full Text] [Related]
35. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
[TBL] [Abstract][Full Text] [Related]
36. Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI.
Kim Y; Cho HH; Kim ST; Park H; Nam D; Kong DS
Neuroradiology; 2018 Dec; 60(12):1297-1305. PubMed ID: 30232517
[TBL] [Abstract][Full Text] [Related]
37. Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma.
Li ZC; Bai H; Sun Q; Zhao Y; Lv Y; Zhou J; Liang C; Chen Y; Liang D; Zheng H
Cancer Med; 2018 Dec; 7(12):5999-6009. PubMed ID: 30426720
[TBL] [Abstract][Full Text] [Related]
38. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
[TBL] [Abstract][Full Text] [Related]
39. Multimodality radiomics analysis based on [
Xu H; Lv W; Zhang H; Yuan Q; Wang Q; Wu Y; Lu L
Eur Radiol; 2023 Oct; 33(10):6677-6688. PubMed ID: 37060444
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
